Search results
Results from the WOW.Com Content Network
The Biomedical Advanced Research and Development Authority (BARDA) is a center within the Administration for Strategic Preparedness and Response [1] (ASPR) located within the U.S. Department of Health and Human Services (HHS) responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear ...
Its functions include preparedness planning and response; building federal emergency medical operational capabilities; countermeasures research, advance development, and procurement; and grants to strengthen the capabilities of hospitals and health care systems in public health emergencies and medical disasters.
On December 19, 2006, the Pandemic and All-Hazards Preparedness Act (PAHPA), Public Law No. 109-417, was signed into law by President George W. Bush.First introduced in the House by Rep. Mike Rogers (R-MI) and Rep. Anna Eshoo (D-CA), PAHPA had broad implications for the United States Department of Health and Human Services's (HHS) preparedness and response activities.
BARDA, a division of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR), works to support the development of medical countermeasures such as vaccines, drugs, and diagnostic tools to counteract health security threats.
BARDA was designed to streamline the development of vaccines, drugs, and medical countermeasures by reducing bureaucratic hurdles and accelerating research and approval processes. The agency aimed to foster collaborations between the government and pharmaceutical companies, offering funding and support for vaccine and drug development while ...
Medical countermeasures (MCMs) are products such as biologics and pharmaceutical drugs that can protect from or treat the effects of a chemical, biological, radiological, or nuclear (CBRN) attack, or in the case of public health emergencies. MCMs can also be used for prevention and diagnosis of symptoms associated with CBRN attacks or threats.
President Biden announced he’d be invoking the Cold War era law to help with supply chain issues.
Section 402 reauthorizes BARDA, which was created in 2006 to help bridge the gap between medical countermeasures development and procurement. It would reauthorize BARDA at $415 million for FY 2013 – 2017, which is equal to the program's FY 2012 appropriated level.